Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Seagen Inc.
KaliVir Immunotherapeutics
IDEAYA Biosciences
iOnctura
Sotio Biotech Inc.
Nuvectis Pharma, Inc.
Seagen Inc.
Novartis
Kezar Life Sciences, Inc.
Bristol-Myers Squibb
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
Novartis
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
Turnstone Biologics, Corp.
Taiho Oncology, Inc.
Ipsen
Symphogen A/S
Aromics Therapeutics
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc
BridGene Biosciences Inc.
Pfizer
NGM Biopharmaceuticals, Inc
Candel Therapeutics, Inc.
Xencor, Inc.
A&G Pharmaceutical Inc.
Ascentage Pharma Group Inc.
Calithera Biosciences, Inc
AbbVie
AbbVie
Eli Lilly and Company
Infinity Pharmaceuticals, Inc.
MacroGenics
Shionogi Inc.
Incyte Corporation
Novartis
Incyte Corporation
Curis, Inc.
Bayer
GlaxoSmithKline
Bayer
Morphotek
Valerio Therapeutics
Valerio Therapeutics